Add Trial
Sign In

KEYNOTE-598 / MK-3475-598 - Hosted By


A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive

Study Type Treatment
Sponsor Name Merck
Disease type Non-Small Cell Lung Cancer
Disease Stage IV
Clinical Status First line
Phase III
Intervention / Treatment Pembrolizumab + Ipilimumab vs Ipilumumab + Placebo
Research Site St. Mary’s Hospital
Investigator Dr Adrian Langleben
Coordinator Dora Bartulovic
Telephone number
Fax number
Study start date October 5, 2017
Study end date
Trial Status Recruiting
Study Type Treatment
Sponsor Name
Tumor Site NSCLC - Non Small Cell Lung Cancer
Disease Stage Stage IV
Clinical Status Advanced Disease 1st Line
Phase Phase I
Intervention / Treatment
Research Site Montreal, QC, St. Mary's Hospital
Telephone Number +1 (514) 345-3511
Fax Number
Study Start Date
Study End Date
Trial Status


Working Hours :

Now Closed UTC - 4
  • MondayDay Off
  • TuesdayDay Off
  • WednesdayDay Off
  • ThursdayDay Off
  • FridayDay Off
  • SaturdayDay Off
  • SundayDay Off

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: KEYNOTE-598 / MK-3475-598

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Account details will be confirmed via email.

Reset Your Password